OptiClear IPL dry eye treatment machine OptiClear dry eye treatment machine OptiClear IPL treatment machine OptiClear IPL treatment for dry eyes ipl machine for dry eye intense pulsed light therapy machine ipl equipment suppliers

OptiClear IPL – Dry Eye Treatment Machine

Advanced Intense Pulsed Light (IPL) technology for the treatment of Dry Eye.

The clinically proven light-based solution for the treatment of Meibomian Gland Dysfunction (MGD), the leading cause of evaporative dry eye disease (DED).

Safe, effective, and rapid treatment of periocular inflammatory conditions such as rosacea and telangiectasia, which can lead to ocular surface conditions such as DED.

Clinically proven technology
Long-term results
No click fees
OptiClear IPL leads the way in Dry Eye treatment

OptiClear IPL brings the power of Intense Pulsed Light (IPL) to your practice with a dedicated light-based solution for the treatment of Meibomian Gland Dysfunction (MGD).

MGD is the leading cause of evaporative dry eye disease. MGD is associated with inflammation of the eyelids as well as a range of symptoms that can greatly interfere with patients’ quality of life. These include dryness, itching, irritation, soreness, eye fatigue and blurred vision. Lifestyle and environmental factors mean that Dry Eye is now more prevalent. It affects a wider demographic, often at earlier life stages. DED is one of the most common conditions optometrists see in their clinics. Around 80% of patients will have some form of Dry Eye.

OptiClear IPL, developed by Alma, is a breakthrough solution that targets the root cause of DED, not just the symptoms. OptiClear IPL is a gentle, non-invasive, yet highly effective treatment that stimulates and unblocks the meibomian glands while relieving surrounding vascular inflammation, bringing your patient long-term relief from MGD. With every pulse of light, this first-of-its-kind, energy-based therapy works to control the inflammatory process to halt the vicious cycle of inflammation, providing long-lasting results.
Clinical evidence has shown that the wavelength range of 550-650 nm relieves the symptoms of MGD and provides effective, long-term relief. OptiClear IPL machine for dry eye harnesses light energy from a precise, narrow band spectrum at this targeted, therapeutic range. Gentle heating liquifies the meibum, unblocks the Meibomian glands and improves blood flow to the area, for enhanced gland function and long-lasting relief.
OptiClear uses Alma’s proprietary AFT, an advanced form of intense pulsed light technology. AFT converts unused UV light outside the therapeutic range into the optimal spectrum, delivering total efficiency and highly effective treatment. Each pulse is delivered with uniform fluence (energy) and controlled peak power, ensuring maximum safety and minimised risks of adverse effects.
Minimal discomfort is achieved through simultaneous contact cooling using a cold sapphire tip which cools the skin during treatment for longer periods of time, resulting in more comfortable treatment for patients.
A dedicated, compact and ergonomic applicator eases clinician comfort and provides maximum visibility of the treatment area. It features an ideal 3cm² spot size for rapid and precise treatment as well as full coverage without overlap.
Procedures with this IPL laser dry eye technology can be performed via a stationary delivery method or using the In-motion™ technique for gradual heat build-up and increased patient comfort.
OptiClear IPL dry eye treatment machine benefits:
  • Proven IPL technology supported by multiple clinical studies
  • Targeted, narrow-band spectrum
  • Versatile treatment options
  • Ergonomic applicator
  • No consumables
  • Quick return on investment
  • A permanent solution to the causes of dry eye
  • Fast, effective, and painless treatment and results
Expand your clinical treatment range

Effective Dry Eye treatment not only relieves what can often be debilitating symptoms but also improves patient outcomes of other vision treatments. Whether your patient has planned cataract surgery or is looking for vision correction solutions such as IPCL, OptiClear IPL intense pulsed light therapy can improve patient tolerance.

Expand your treatment range and quickly realise a return on investment with this dedicated solution for optometrists and ophthalmologists.

Technical specifications
Brochures & Manuals
Description & Technical Specs
System Dimensions (W x D x H): 56 x 47 x 45 cm
Weight: 40 kg
Electrical Requirements: 220/230VAC, 7A, 50/60 Hz, single phase
System Control: Fully computerised, microprocessor-based
Graphic User Interface: High-resolution, colour LCD display, Touch-screen technology.
Emission Indicators:
  • Visual, illuminating yellow indicator:
  • OFF when no emission occurs.
  • Blinking during Ready mode.
  • Illuminating continuously during light emission.
  • Audible indicator:
  • Activated during light emission, when pressing the operation buttons (user-controlled) and upon detection of an error condition.
EN 60825-1: Class 4
IEC 60601-2-57: Risk Group 3
Mode of Protection against Electric Shock: Class I Equipment
Degree of Protection against Electric Shock: Type B Applied Part



Intense pulsed light (IPL) therapy is a non-invasive treatment using high-energy flashes of light between 400–1200 nm lasting several milliseconds. This is converted into heat and results in selective tissue thermolysis. The mechanism of action of IPL in MGD is commonly related to thermocoagulation of vascular telangiectasia, antimicrobial effects, and a direct effect on abnormal lipids. Data shows that IPL either alone or combined with gland expression results in improved symptoms and tear film stability. IPL for MGD is performed with a scleral shield protection of the globe to avoid, intraocular damage.

OptiClear IPL is an advanced dry eye treatment machine that utilises the latest in intense pulsed light therapy technology to alleviate the symptoms of dry eye and meibomian gland dysfunction (MGD). This state-of-the-art IPL treatment device is designed to target the root cause of dry eye and MGD by stimulating the meibomian glands in the eyelids, improving oil production and reducing inflammation.

The OptiClear IPL is a high-end device that is easy to use, non-invasive and provides a safe and effective solution to use on patients who suffer from dry eye and MGD.

Clinical studies have shown that intense pulsed light therapy is highly effective in relieving the symptoms of dry eye and MGD. Patients report a significant reduction in dryness, itching, and burning sensations, as well as an improvement in overall eye comfort and function. The OptiClear IPL is a long-term solution that can help patients achieve lasting relief from dry eye symptoms, allowing them to return to their normal activities and enjoy life to the fullest.

Investing in the OptiClear IPL creates a long-term dry eye treatment solution for your patients. With its advanced technology and proven results, this product is the premium intense pulsed light therapy machine for anyone looking to improve patient outcomes with cutting-edge optometry light therapy devices. Contact us today for further information on OptiClear IPL, clinical insights, examples of practice transformation and patient pathway development.

Intense Pulsed Light (IPL) therapy is the newest and most promising form of therapy for chronic blepharitis, meibomian gland dysfunction (MGD), telangiectasias, rosacea, and dry eye. IPL can halt chronic inflammatory processes, eliminate bacteria and mites, and can restimulate the meibomian glands.


Blepharitis (inflammation of the eyelids) usually affects both eyes along the edges of the eyelids. Blepharitis commonly occurs when tiny oil glands near the base of the eyelashes become clogged, causing irritation and redness. Once the lid is inflamed, inflammation will spread to the meibomian glands.

IPL therapy in patients with moderate to severe acute blepharitis or blepharoconjunctivitis, effectively improves clinical signs, providing symptomatic relief. IPL uses gentle pulses of light to target the eyelids, helping to open glands and liquefy the oils in them to reduce inflammation and any associated bacterial growth in the area around the eyes.

Meibomian Gland Dysfunction (MGD)

MGD leads to changes in meibum quality and quantity that can cause evaporative dry eye and ocular surface disruption, leading to dry eye symptoms in some individuals. MGD and dry eye are commonly grouped together due to their similar symptoms, such as itching, burning, and irritation. However, while dry eye is caused by a lack of tears, MGD is due to a lack of oil production to protect the tears. MGD is more than just 'dry eyes'. Symptoms may progress for those with MGD which, if left untreated, can result in gland atrophy (permanent damage to the eyes).

Intense pulsed light (IPL) therapy is a promising treatment option for those who suffer from Meibomian Gland Dysfunction (MGD). This innovative therapy works by delivering pulses of light to the meibomian glands located in the eyelids. By applying heat to these glands, IPL therapy can improve the flow of oils to the surface of the eyes and reduce inflammation, which can provide relief from MGD symptoms. Intense pulsed light (IPL) has some potential to reverse gland atrophy.


People with rosacea are often unaware that it can also develop in their eyes. Ocular rosacea is a condition where the eyes become inflamed and irritated. It often occurs in people who have the skin condition rosacea, although not in all cases. Typical symptoms of rosacea include a red appearance to the skin, pimples, and visible blood vessels.

Intense pulsed light (IPL) therapy can be an effective treatment option for rosacea sufferers. IPL therapy utilises pulses of light to target the blood vessels that contribute to the redness and inflammation associated with rosacea. The heat from the light causes the blood vessels to constrict, reducing redness and inflammation. Over time, the treated vessels may break down and be reabsorbed by the body, further improving the appearance of the skin.

Clinical studies have shown that IPL therapy can be highly effective in reducing the redness and flushing associated with rosacea. The treatment is non-invasive and requires no downtime, allowing patients to return to their normal activities immediately following treatment.


Telangiectasia (visible red thin lines on the skin surface) often appear in spider-like formations, commonly referred to as spider veins. Telangiectasia are dilated or broken blood vessels often seen on the face, especially around the nose and across the cheeks. They are classified into four different types: simple, arborising, spider and papular.

Intense pulsed light (IPL) therapy has become a popular treatment option for individuals with Telangiectasia. IPL therapy treats thread veins by emitting wavelengths of light that are filtered to target the haemoglobin in the thread veins/broken capillaries. The spider vein absorbs the pulsed light, which converts to heat and coagulates the vessel. If treatment is effective, the vein will gradually break down over several days until it disappears. Deeper, thicker veins may take longer to disappear completely.

Spectrum is a leading and highly regarded supplier of IPL equipment, offering advanced devices specifically designed for the treatment of dry eye syndrome and commonly linked conditions. If you are interested in learning more about the OptiClear IPL machine, contact us today to arrange a demo.

The diagnosis and management of long-term chronic ailments such as Dry Eye Disease (DED) fall outside the scope of treatment provided by the NHS. Community-based eyecare presents significant opportunities for optometrists.

Independent optometrists are uniquely positioned to change the landscape of community optometry. Through workforce upskilling and embracing specialised treatments, they can educate, diagnose, and provide a range of primary eyecare services that deliver improved patient outcomes; and are also more profitable.

Dry eye syndrome happens when the eyes don’t make enough tears, or the tears dry too quickly, depriving the eyes of essential moisture and hydration.

Dry eye disease (DED) may have multiple contributory factors including tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities.

MGD is not a single entity but multifactorial in origin. Causes include:

  • the congenital absence of meibomian glands such as in ectodermal dysplasia
  • abnormal blinking (reduced rate and amplitude) seen in conditions like dementia and Parkinson’s disease and compromising lipid outflow
  • obstruction of the meibomian terminal ductules such as in Stevens-Johnson syndrome due to keratinization of the lid margin
  • structural damage to the glands caused by cicatricial diseases
  • inflammation of the glands such as in rosacea; and direct disruption of the lipid layer caused by topical medications

The overall impact of MGD is a loss of the normal lipid layer of the tear film that can result in an evaporative form of DED. In severe disease, there is permanent gland atrophy, scarring and erosion of the posterior lid margin, altered microbial flora of the ocular surface and chronic inflammation.

DED can affect people of any age. Symptoms are associated with negative impacts on socioemotional functioning, vision-related QoL function, daily activities and work productivity.

Eyes that lack moisture dry out and become red, swollen, and irritated. Symptoms tend to affect both eyes with a gritty, burning, or foreign body sensation. Some people may also notice stringy mucus or discharge from the eyes. The majority of dry eye syndrome comes down to the fact that tears are evaporating too quickly.

Key symptoms of dry eye include:

  • itchiness
  • burning sensation
  • soreness
  • grittiness
  • redness
  • blurred vision
  • light sensitivity
  • eye fatigue
  • excessive tearing (as the constituents of the tears change)
  • crusting along the eyelid margins
  • Dry eye disease (DED) is a commonly occurring ocular condition and a frequent reason for patients to seek medical eye care.

    Approximately one-third of the adult UK population have DED, a debilitating and potentially painful eye condition, a figure which has more than doubled in the past year. The prevalence of DED in the UK is higher in women compared with men and increases with age, with most individuals with DED aged over 50 years.

    Research from the University of Aston in Birmingham has found that there are an increasing number of children and young people suffering from dry eye disease. This is likely because of blink rate reduction through prolonged screen use.